Aclaris Therapeutics, Inc.
NASDAQ:ACRS
1.18 (USD) • At close September 13, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 31.249 | 29.752 | 6.761 | 6.482 | 4.227 | 10.091 | 1.683 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 18.081 | 11.96 | 4.713 | 5.133 | 4.055 | 6.85 | 1.207 | 0.12 | 0.09 | 0 | 0 |
| Gross Profit
| 13.168 | 17.792 | 2.048 | 1.349 | 0.172 | 3.241 | 0.476 | -0.12 | -0.09 | 0 | 0 |
| Gross Profit Ratio
| 0.421 | 0.598 | 0.303 | 0.208 | 0.041 | 0.321 | 0.283 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 98.384 | 77.813 | 43.813 | 31.731 | 64.899 | 63.009 | 39.79 | 33.476 | 15.339 | 6.507 | 3.488 |
| General & Administrative Expenses
| 31.098 | 25.133 | 23.619 | 20.53 | 27.156 | 27.649 | 33.109 | 15.091 | 5.328 | 2.026 | 1.769 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0.283 | 0.671 | 47.997 | 0.085 | 3.295 | 0 | 0 | 0 |
| SG&A
| 31.098 | 25.133 | 23.619 | 20.53 | 27.827 | 75.646 | 33.109 | 15.091 | 5.328 | 2.026 | 1.769 |
| Other Expenses
| 8.509 | 2.946 | -1.142 | -0.424 | -2.484 | 2.676 | 2.07 | 0.488 | 0 | 0 | 0 |
| Operating Expenses
| 129.482 | 102.946 | 67.432 | 52.261 | 92.726 | 138.655 | 72.899 | 48.567 | 20.667 | 8.533 | 5.257 |
| Operating Income
| -97.357 | -85.154 | -65.384 | -50.912 | -111.058 | -135.414 | -72.423 | -48.567 | -20.667 | -8.533 | -5.257 |
| Operating Income Ratio
| -3.116 | -2.862 | -9.671 | -7.854 | -26.273 | -13.419 | -43.032 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 27.466 | -1.754 | -25.481 | -0.424 | -2.484 | 2.676 | 2.07 | 0.488 | 0.104 | 0.016 | 0.021 |
| Income Before Tax
| -88.848 | -86.908 | -90.865 | -51.336 | -113.542 | -132.738 | -70.353 | -48.079 | -20.563 | -8.517 | -5.236 |
| Income Before Tax Ratio
| -2.843 | -2.921 | -13.44 | -7.92 | -26.861 | -13.154 | -41.802 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| -0.367 | 1.754 | 23.416 | -0.182 | 29.308 | 2.676 | -1.83 | -0.12 | -0.09 | 0 | 0 |
| Net Income
| -88.481 | -88.662 | -114.281 | -51.154 | -142.85 | -132.738 | -68.523 | -48.079 | -20.563 | -8.517 | -5.236 |
| Net Income Ratio
| -2.831 | -2.98 | -16.903 | -7.892 | -33.795 | -13.154 | -40.715 | 0 | 0 | 0 | 0 |
| EPS
| -1.27 | -1.36 | -2.01 | -1.2 | -3.46 | -4.03 | -2.44 | -2.25 | -3.37 | -0.8 | -0.49 |
| EPS Diluted
| -1.27 | -1.36 | -2.01 | -1.2 | -3.46 | -4.03 | -2.44 | -2.25 | -3.37 | -0.8 | -0.49 |
| EBITDA
| -134.408 | -79.657 | -41.045 | -50.912 | -74.05 | -135.414 | -72.423 | -48.567 | -20.667 | -8.521 | -5.246 |
| EBITDA Ratio
| -4.301 | -2.677 | -6.071 | -7.854 | -17.518 | -13.419 | -43.032 | 0 | 0 | 0 | 0 |